146
Views
7
CrossRef citations to date
0
Altmetric
Review

Cefditoren in upper and lower community-acquired respiratory tract infections

, &
Pages 85-94 | Published online: 09 Feb 2011

References

  • MogyorosMChallenges of managed care organisations in treating respiratory tract infections in an age of antibiotic resistanceAm J Man Care20017Suppl 6163169
  • LlorCConsideraciones a la hora de la prescripción antibiótica en atención primariaMed Clin Monogr (Barc)200455257
  • HuovinenPCarsOControl of antimicrobial resistance: time for action. The essentials of control are already well knownBMJ19983176136149727984
  • García-ReyCFenollAAguilarLCasalJEffect of social and climatological factors on antimicrobial use and Streptococcus pneumoniae resistance in different provinces in SpainJ Antimicrob Chemother20045446547115269198
  • GranizoJJAguilarLCasalJGarcía-ReyCDal-RéRBaqueroFStreptococcus pneumoniae resistance to erythromycin and penicillin in relation to macrolide and beta-lactam consumption in Spain (1979–1997)J Antimicrob Chemother20004676777311062196
  • García-ReyCAguilarLBaqueroFCasalJDal-RéRImportance of local variations in antibiotic consumption and geographical differences of erythromycin and penicillin resistance in Streptococcus pneumoniaeJ Clin Microbiol20024015916411773111
  • GómezJRuiz-GómezJHernández-CardonaJLNuñezMLCanterasMValdésMAntibiotic resistance patterns of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis: a prospective study in Murcia, Spain, 1983–1992Chemotherapy1994402993037956452
  • GranizoJJAguilarLCasalJDal-RéRBaqueroFStreptococcus pyogenes resistance to erythromycin in relation to macrolide consumption in Spain (1986–1997)J Antimicrob Chemother20004695996411102415
  • García-ReyCAguilarLBaqueroFCasalJMartínJEPharmacoepidemiological analysis of provincial differences between consumption of macrolides and rates of erythromycin resistance among Streptococcus pyogenes isolates in SpainJ Clin Microbiol2002402959296312149359
  • Pérez-TralleroEGarcía-de-la-FuenteCGarcía-ReyCGeographical and ecological analysis of resistance, coresistance, and coupled resistance to antimicrobials in respiratory pathogenic bacteria in SpainAntimicrob Agents Chemother2005491965197215855520
  • Gómez-LusRGranizoJJAguilarLBouzaEGutierrezAGarcía-de-LomasJIs there an ecological relationship between rates of antibiotic resistance of species of the genus Streptococcus? The Spanish Surveillance Group for Respiratory PathogensJ Clin Microbiol1999373384338610488213
  • RichterSSHeilmannKPBeekmannSEMacrolide-resistant Streptococcus pyogenes in the United States, 2002–2003Clin Infect Dis20054159960816080080
  • ChanJCChuYWChuMYCheungTKLoJYEpidemiological analysis of Streptococcus pyogenes infections in Hong KongPathology20094168168620001348
  • GraciaMDíazCCoronelPAntimicrobial susceptibility of Streptococcus pyogenes in Central, Eastern, and Baltic European Countries, 2005 to 2006: the cefditoren surveillance programDiagn Microbiol Infect Dis200964525619232860
  • Pérez-TralleroEMartín-HerreroJEMazónAAntimicrobial resistance among respiratory pathogens in Spain: latest data and changes over 11 years (1996–1997 to 2006–2007)Antimicrob Agents Chemother2010542953295920439616
  • PrietoJCalvoAGómez-LusMLAntimicrobial resistance: a class effect?J Antimicrob Chemother200250Suppl S2712
  • Clinical and Laboratory Standards InstitutePerformance standards for antimicrobial susceptibility testing; nineteenth informational supplement. CLSI document M100-S19Clinical and Laboratory Standards InstituteWayne, PA USA2009
  • SahmDFBrownNPThornsberryCJonesMEAntimicrobial susceptibility profiles among common respiratory tract pathogens: a GLOBAL perspectivePostgrad Med20081203 Suppl 1162418931467
  • SahmDFBrownNPDraghiDCEvangelistaATYeeYCThornsberryCTracking resistance among bacterial respiratory tract pathogens: summary of findings of the TRUST Surveillance Initiative, 2001–2005Postgrad Med20081203 Suppl 181518931466
  • JansenWTVerelABeitsmaMVerhoefJMilatovicDLongitudinal European surveillance study of antibiotic resistance of Haemophilus influenzaeJ Antimicrob Chemother20065887387716891323
  • SevillanoDGiménezMJCercenadoEGenotypic versus phenotypic characterization, with respect to beta-lactam susceptibility, of Haemophilus influenzae isolates exhibiting decreased susceptibility to beta-lactam resistance markersAntimicrob Agents Chemother20095326727018955529
  • NikiYHanakiHMatsumotoTNationwide surveillance of bacterial respiratory pathogens conducted by the Japanese Society of Chemotherapy in 2007: general view of the pathogens’ antibacterial susceptibilityJ Infect Chemother20091515616719554400
  • SakataHToyonagaYSatoYNationwide survey of the development of drug-resistance in the pediatric field: drug sensitivity of Haemophilus influenzae in JapanJ Infect Chemother20091540240920012732
  • PericMBozdoganBJacobsMRAppelbaumPCEffects of an efflux mechanism and ribosomal mutations on macrolide susceptibility of Haemophilus influenzae clinical isolatesAntimicrob Agents Chemother2003471017102212604536
  • CantónRUnalSFarrellDJAntibacterial resistance patterns in Streptococcus pneumoniae isolated from elderly patients: PROTEKT years 1–5 (1999–2004)Int J Antimicrob Agents20073054655017931834
  • DarabiAHocquetDDowzickyMJAntimicrobial activity against Streptococcus pneumoniae and Haemophilus influenzae collected globally between 2004 and 2008 as part of the Tigecycline Evaluation and Surveillance TrialDiagn Microbiol Infect Dis201067788620385351
  • Pérez-TralleroEGarcía-de-la-FuenteCGarcía-ReyCGeographical and ecological analysis of resistance, coresistance, and coupled resistance to antimicrobials in respiratory pathogenic bacteria in SpainAntimicrob Agents Chemother2005491965197215855520
  • FenollAGranizoJJAguilarLTemporal trends of invasive Streptococcus pneumoniae serotypes and antimicrobial resistance patterns in Spain from 1979 to 2007J Clin Microbiol2009471012102019225097
  • FenollAAguilarLGranizoJJHas the licensing of respiratory quinolones for adults and the 7-valent pneumococcal conjugate vaccine (PCV-7) for children had herd effects with respect to antimicrobial non-susceptibility in invasive Streptococcus pneumoniae?J Antimicrob Chemother2008621430143318819966
  • WhitneyCGFarleyMMHadlerJDecline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccineN Engl J Med20033481737174612724479
  • FenollAAguilarLGiménezMJSusceptibility of recently collected Spanish pneumococci nonsusceptible to oral penicillin from serotypes not included in the 7-valent conjugate vaccineAntimicrob Agents Chemother2010542696269820308373
  • FenollAAguilarLViciosoMDSerotype distribution and susceptibility of Streptococcus pneumoniae isolates from pleural fluid in the current decade in SpainAntimicrob Agents Chemother2010545387539020921314
  • PicazoJRuiz-ContrerasJCasado-FloresJRelations between serotypes, age and clinical presentation of invasive pneumococcal disease in Madrid after the introduction of the 7-valent pneumococcal conjugate vaccine into the vaccination calendarClin Vaccine Immunol201118899421047996
  • Pérez-TralleroEMarimónJMErcibengoaMGiménezMJCoronelPAguilarLAntimicrobial susceptibilities of amoxycillin-non-susceptible and susceptible isolates among penicillin-non-susceptible Streptococcus pneumoniaeClin Microbiol Infect20071393794017617182
  • SorianoFCafiniFAguilarLBreakthrough in penicillin resistance? Streptococcus pneumoniae isolates with penicillin/cefotaxime MICs of 16 mg/L and their genotypic and geographical relatednessJ Antimicrob Chemother2008621234124018799472
  • Rodríguez-CerratoVGraciaMDel PradoGAntimicrobial susceptibility of multidrug-resistant Streptococcus pneumoniae strains with penicillin MICs of 8 to 32 mg/LDiagn Microbiol Infect Dis20106633633819939599
  • WellingtonKCurranMPCefditoren pivoxil: a review of its use in the treatment of bacterial infectionsDrugs2004642597261815516158
  • YamadaMWatanabeTMiyaraTCrystal structure of cefditoren complexed with Streptococcus pneumoniae penicillin-binding protein 2X: structural basis for its high antimicrobial activityAntimicrob Agents Chemother2007514550
  • GraciaMDíazCCoronelPAntimicrobial susceptibility of Haemophilus influenzae and Moraxella catarrhalis isolates in eight Central, East and Baltic European countries in 2005–06: results of the Cefditoren Surveillance StudyJ Antimicrob Chemother2008611180118118316820
  • García-de-LomasJLermaMCebriánLInfluence of Haemophilus influenzae beta-lactamase production and/or ftsI gene mutations on in vitro activity of and susceptibility rates to aminopenicillins and second- and third-generation cephalosporinsInt J Antimicrob Agents20073019019217459665
  • SorianoFGranizoJJFenollAAntimicrobial resistance among clinical isolates of Streptococcus pneumoniae isolated in four southern European countries (ARISE project) from adult patients: results from the cefditoren surveillance programJ Chemother20031510711212797384
  • SorianoFCoronelPGimenoMJiménezMGarcía-CorbeiraPFernández-RoblasRInoculum effect and bactericidal activity of cefditoren and other antibiotics against Streptococcus pneumoniae, Haemophilus influenzae, and Neisseria meningitidisEur J Clin Microbiol Infect Dis1996157617638922582
  • SádabaBAzanzaJRQuetglasEGPharmacokinetic/pharmacodynamic serum and urine profile of cefditoren following single-dose and multiple twice- and thrice-daily regimens in healthy volunteers: a phase I studyRev Esp Quimioter200720516017530036
  • CraigWAPharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and menClin Infect Dis1998261109455502
  • HeffelfingerJDDowellSFJorgensenJHManagement of community-acquired pneumonia in the era of pneumococcal resistance: a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working GroupArch Intern Med20001601399140810826451
  • GranizoJJSádabaBHonoratoJMonte Carlo simulation describing the pharmacodynamic profile of cefditoren in plasma from healthy volunteersInt J Antimicrob Agents20083139639818178067
  • MoelleringRCEliopoulosGMPrinciples of anti-infective therapyMandellGLBennettJEDolinRMandell, Douglas, and Bennett Principles and Practice of Infectious Diseases6th edPhiladelphiaElsevier Churchill Livingstone2005242253
  • CafiniFYusteJGiménezMJEnhanced in vivo activity of cefditoren in pre-immunized mice against penicillin-resistant S. pneumoniae (serotypes 6B, 19F and 23F) in a sepsis modelPLoS One201058e1204120706584
  • SevillanoDAguilarLAlouLHigh protein binding and cidal activity against penicillin-resistant S. pneumoniae: a cefditoren in vitro pharmacodynamic simulationPLoS One200837e271718648650
  • KarlowskyJAJonesMEDraghiDCCritchleyIAThornsberryCSahmDFIn vitro susceptibility of recent clinical isolates of pneumococci to the investigational cephalosporin cefditorenDiagn Microbiol Infect Dis200242596411821173
  • JohnsonDMBiedenbachDJBeachMLPfallerMAJonesRNAntimicrobial activity and in vitro susceptibility test development for cefditoren against Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus speciesDiagn Microbiol Infect Dis2000379910510863104
  • JonesRNBiedenbachDJCrocoMABarrettMSIn vitro evaluation of a novel orally administered cephalosporin (Cefditoren) tested against 1249 recent clinical isolates of Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniaeDiagn Microbiol Infect Dis1998315735789764398
  • Agencia Española de Medicamentos y Productos Sanitarios https://sinaem4.agemed.es/consaem/fichasTecnicas.do?metodo=detalleForm.
  • Food and Drug AdministrationSpectracef prescribing information http://www.crtx.com/docs/spectracef.pdf.
  • WeinbergerDMDaganRGivon-LaviNEpidemiologic evidence for serotype-specific acquired immunity to pneumococcal carriageJ Infect Dis20081971511151818471062
  • SoininenAPursiainenHKilpiTKäyhtyHNatural development of antibodies to pneumococcal capsular polysaccharides depends on the serotype: association with pneumococcal carriage and acute otitis media in young childrenJ Infect Dis200118456957611494163
  • FelminghamDRobbinsMJGhoshGAn in vitro characterization of cefditoren, a new oral cephalosporinDrugs Exp Clin Res1994201271477813385
  • GranizoJJGiménezMJBarberánJCoronelPGimenoMAguilarLEfficacy of cefditoren in the treatment of upper respiratory tract infections: a pooled analysis of six clinical trialsRev Esp Quimioter200821142118443928
  • OzakiTNishimuraNSuzukiMFive-day oral cefditoren pivoxil versus 10-day oral amoxicillin for pediatric group A streptococcal pharyngotonsillitisJ Infect Chemother20081421321818574657
  • KikutaHShibataMNakataSComparative study of 5-day and 10-day cefditoren pivoxil treatments for recurrent group A beta-hemolytic Streptococcus pharyngitis in childrenInt J Pediatr200986360820041005
  • PoachanukoonOKitcharoensakkulMEfficacy of cefditoren pivoxil and amoxicillin/clavulanate in the treatment of pediatric patients with acute bacterial rhinosinusitis in Thailand: a randomized, investigator-blinded, controlled trialClin Ther2008301870187919014842
  • GranizoJJGiménezMJBarberánJCoronelPGimenoMAguilarLThe efficacy of cefditoren pivoxil in the treatment of lower respiratory tract infections, with a focus on the per-pathogen bacteriologic response in infections caused by Streptococcus pneumoniae and Haemophilus influenzae: a pooled analysis of seven clinical trialsClin Ther2006282061206917296462
  • CaseyJRPichicheroMEThe evidence base for cephalosporin superiority over penicillin in streptococcal pharyngitisDiagn Microbiol Infect Dis2007573 SupplS39S45
  • BudhaniRKStruthersJKInteraction of Streptococcus pneumoniae and Moraxella catarrhalis: investigation of the indirect pathogenic role of beta-lactamase-producing moraxellae by use of a continuous-culture biofilm systemAntimicrob Agents Chemother199842252125269756750
  • CaseyJRPichicheroMEMeta-analysis of cephalosporins versus penicillin for treatment of group A streptococcal tonsillopharyngitis in adultsClin Infect Dis2004381526153415156437
  • SevillanoDAguilarLAlouLBeta-lactam effects on mixed cultures of common respiratory isolates as an approach to treatment effects on nasopharyngeal bacterial population dynamicsPLoS One2008312e384619052648
  • Alvarez-SalaJLKardosPMartínez-BeltránJCoronelPAguilarLClinical and bacteriological efficacy in treatment of acute exacerbations of chronic bronchitis with cefditoren-pivoxil versus cefuroxime-axetilAntimicrob Agents Chemother2006501762176716641447
  • GranizoJJAguilarLGimenezMJCoronelPGimenoMPrietoJSafety profile of cefditoren. A pooled analysis of data from clinical trials in community-acquired respiratory tract infectionsRev Esp Quimioter200922576119544097
  • AlmiranteBCamposJCantónRPrudent use of antimicrobials: have we done the best we can? The SEIMC and REIPI statementEnferm Infecc Microbiol Clin20102848548620817357
  • BaqueroFGarauJPrudent use of antimicrobial agents: revisiting concepts and estimating perspectives in a global worldEnferm Infecc Microbiol Clin20102848748820846754
  • DanemanNLowDEMcGeerAGreenKAFismanDNAt the threshold: defining clinically meaningful resistance thresholds for antibiotic choice in community-acquired pneumoniaClin Infect Dis2008461131113818444846